KENILWORTH, N.J.--(BUSINESS WIRE)--ILÚM Health Solutions, a provider of innovative technology and services to support infectious disease management, today announced it has acquired Teqqa LLC, which provides precision analytics for infectious disease management. Teqqa has been a development partner with ILÚM since the latter’s founding; this acquisition formalizes and strengthens the ongoing relationship. Details of the transaction were not disclosed.
“This acquisition helps reinforce ILÚM’s vision to transform the way hospitals manage infectious diseases,” says Paul Edwards, managing director, ILÚM. “The acquisition strengthens ILÚM’s ability to help hospitals efficiently target patients and accelerate time to appropriate interventions; efficiently and consistently track performance, prescribing, and patient outcomes; and enhance timely communication and clinical collaboration within the workflow.”
ILÚM, created by Merck’s Healthcare Services and Solutions (HSS)division, is collaborating with healthcare providers to improve infectious disease outcomes through the use of clinical decision support and electronic patient data, as well as tech-enabled solutions to facilitate antimicrobial stewardship programs and sepsis management.
The Centers for Disease Control and Prevention estimates that annually in the United States we face 2 million illnesses, 23,000 deaths and $35 billion in lost productivity – all attributable to antibiotic resistance.
Teqqa has deep experience working with hospitals to implement disease surveillance solutions and turn lab and medication data into actionable information. One example is Teqqa’s Precision Antibiotic Therapy (PAT™) analytic, which integrates patient-specific risk factors from the longitudinal record to offer timely insights for antibiotic use.
“In antibiotic stewardship, our ultimate goal is to make sure the right patients get the right antibiotic at the right time,” says Dr. Keith Hamilton, associate healthcare epidemiologist and director of Antimicrobial Stewardship at the Hospital of the University of Pennsylvania, which has been collaborating with Teqqa since 2014. “These solutions make previously unavailable data useable at the point of prescription. Our clinicians now have data at their fingertips to help them make the most appropriate decisions when it matters most. We look forward to collaborating with ILÚM to further validate how these solutions support the best possible outcomes for our patients.”
About ILÚM Health Solutions
ILÚM Health Solutions is a provider of technology and services to support infectious disease management. ILÚM is part of Healthcare Services & Solutions, LLC, a wholly-owned subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada), an independent business unit focused on improving the value of care delivered to patients through evidence-based services and solutions. ILÚM is organized and managed independently from Merck’s pharmaceutical products business. For more information, visit www.ILÚMhealthsolutions.com and connect with us on Twitterand LinkedIn.
About Teqqa
Teqqa provides precision analytics for infectious disease management. Through its software and mobile applications, Teqqa helps hospitals optimize antibiotic use and combat antimicrobial resistance. At the University of Pennsylvania, Penn Medicine relies on Teqqa tools to power their antimicrobial stewardship program. Teqqa is located in Jackson, WY and was founded in 2013. For more information on Teqqa’s solutions, visit www.teqqa.com.
About Merck
For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.
